Literature DB >> 6284840

On the mechanism of enhanced monocyte and neutrophil cytotoxicity in severe psoriasis.

T Herlin, N Borregaard, K Kragballe.   

Abstract

Monocyte and neutrophil function assessed as antibody-dependent cell-mediated cytotoxicity (ADCC) using IgG-sensitizing human erythrocytes as target cells was enhanced in patients with severe psoriasis when compared to healthy controls. We found significant correlation between increased monocyte ADCC and increased neutrophil ADCC, No differences in basal cAMP levels and cAMP responses during initiation of the ADCC reaction was observed between psoriatics and normals. Also degranulation determined as lysozyme release during ADCC was normal. In contrast, the increase in ADCC was significantly correlated to an enhanced hexose monophosphate shunt activation in the effector cells during the cytotoxic reaction. Activity of enzymes responsible for the respiratory burst was not altered in psoriasis since superoxide production after stimulation with phorbol myristate acetate was normal. Likewise, oxygen consumption and degranulation following phagocytosis of opsonized zymosan particles in neutrophils was found normal in psoriasis. Since monocytes showed increased binding of IgG-sensitized erythrocytes these data indicate that the enhanced monocyte and neutrophil ADCC is caused by an enhancement of the respiratory burst possibly induced by increased Fc receptor activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6284840     DOI: 10.1111/1523-1747.ep12500035

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

1.  Leukopheresis for treatment of psoriasis: is therapeutical benefit related to reduced activities of neutral proteinases of polymorphonuclear leukocytes?

Authors:  W Gliński; D Barszcz; S Jabłońska; Z Zarebska; M Tigałonowa; E Janczura
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

2.  Decreased extracellular release of granule enzymes from in vitro-stimulated polymorphonuclear leukocytes in guttate psoriasis.

Authors:  W Glinski; M Tigalonowa; S Jablonska; E Janczura
Journal:  Inflammation       Date:  1986-06       Impact factor: 4.092

3.  Increased rate of opsonization of zymosan by serum from patients with psoriasis.

Authors:  T Herlin; N Borregaard
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

4.  Studies of the effect of D-penicillamine and sodium aurothiomalate therapy on superoxide anion production by monocytes from patients with rheumatoid arthritis: evidence for in vivo stimulation of monocytes.

Authors:  N P Hurst; A L Bell; G Nuki
Journal:  Ann Rheum Dis       Date:  1986-01       Impact factor: 19.103

5.  Basement membrane zone as a target for human neutrophil elastase in psoriasis.

Authors:  W Glinski; M Jarzabek-Chorzelska; M Kuligowski; M Pierozynska-Dubowska; M Glinska-Ferenz; S Jabłonska
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

6.  Defective natural-killer- and killer-cell activity associated with increased polymorphonuclear leukocyte adherence in psoriasis.

Authors:  S Majewski; M Wasik; S Jabłońska; M Kamiński; M Fraczykowska
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

7.  Colchicine in generalized pustular psoriasis: clinical response and antibody-dependent cytotoxicity by monocytes and neutrophils.

Authors:  H Zachariae; K Kragballe; T Herlin
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

8.  Augmented glucose-6-phosphate dehydrogenase activity and normal penetration and metabolism of dehydroepiandrosterone in mononuclear leukocytes in psoriasis.

Authors:  R E Schopf; F J Müller; P Benes; B Morsches
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

Review 9.  Plasma total antioxidant capacity and peroxidation biomarkers in psoriasis.

Authors:  Ilaria Peluso; Arturo Cavaliere; Maura Palmery
Journal:  J Biomed Sci       Date:  2016-07-04       Impact factor: 8.410

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.